advertising
- Background
- Methods
- Results
- Conclusions
- Participants and Methods
- Inclusion Criteria
- Exclusion Criteria
- Study Groups
- Grades of DFU
- Evaluation of Vascular Circulation
- Evaluation of Osteomyelitis
- Evaluation of Infection Symptoms and Treatment
- Evaluation of Neuropathy
- Evaluation of Treatment Success
- Termination of Treatment
- Surgical Debridement Procedure
- Termination of Debridement Treatment
- Application of Negative Pressure Wound Therapy
- Assessment of Wound Recovery
- Application of Intralesional EGF
- Graft Application
- Statistical Analysis
- Results
- Discussion
- Conclusions
- References
-
1.
Frykberg RG , Zgonis T & Armstrong DG et al.; American College of Foot and Ankle Surgeons: Diabetic foot disorders: a clinical practice guideline 2006 revision. J Foot Ankle Surg 45: 1, 2006.
-
2.
Reiber GE , Vileikyte L & Boyko EJ et al.: Causal pathways for incident lower-extremity ulcers in patients with diabetes from two settings. Diabetes Care 22: 157, 1999.
-
3.
Slovenkai MP: Foot problems in diabetes. Med Clin North Am 82: 49, 1998.
-
4.
Calvet HM & Yoshicawa TT: Infections in diabetes. Infect Dis Clin North Am 15: 407, 2001.
-
5.
Demir Y , Demir S & Gökce C: Diabetic foot: physiopathology, diagnosis and current therapeutic approach before reconstruction. Med J Kocatepe 5: 1, 2004.
-
6.
Bonassar LJ & Trippel SB: Interaction of epidermal growth factor and insulin-like growth factor-1 in the regulation of growth plate chondrocytes. Exp Cell Res 234: 1, 1997.
-
7.
Cohen S: Isolation of a mouse submaxillary gland protein accelerating incisor eruption and eyelid opening in the new-born animal. J Biol Chem 237: 1555, 1962.
-
8.
Nanney LB: Epidermal and dermal effects of epidermal growth factor during wound repair. J Invest Dermatol 94: 624, 1990.
-
9.
Wagner FW Jr : “The Diabetic Foot and Amputation of the Foot,” in Surgery of the Foot, p 421, Mosby, St. Louis, 1986.
-
10.
Gerhard-Herman MD , Gornik HL & Barrett C et al.: 2016 AHA/ACC guideline on the management of patients with lower extremity peripheral artery disease: a report of American Collage of Cardiology/American Heart Association task force on clinical practice guidelines. Circulation 135: 726, 2017.
-
11.
Lipsky BA , Berendt AR & Deery HG et al.; Infectious Diseases Society of America: Diagnosis and treatment of diabetic foot infections. Clin Infect Dis 39: 885, 2004.
-
12.
Boonstra J , Rijken P & Humbel B et al.: The epidermal growth factor. Cell Biol Int 19: 413, 1995.
-
13.
Han SK , Choi KJ & Kim WK: Clinical application of fresh fibroblast allografts for the treatment of diabetic foot ulcers: a pilot study. Plast Reconstr Surg 114: 1783, 2004.
-
14.
Berlanga-Acosta J: Diabetic lower extremity wounds: the rationale for growth factors-based infiltration treatment. Int Wound J 8: 612, 2011.
-
15.
Bordianu A , Bobircã F & Pãtraæcu T: Skin grafting in the treatment of diabetic foot soft tissue defects. Chirurgia 113: 644, 2018.
-
16.
Lee KN , Ben-Nakhi M & Park EJ et al.: Cyclic negative pressure wound therapy: an alternative mode to intermittent system. Int Wound J 12: 686, 2015.
-
17.
Bobircã F , Mihalache O & Georgescu D et al.: The new prognostic-therapeutic index for diabetic foot surgery: extended analysis. Chirurgia (Bucur) 111: 151, 2016.
-
18.
Jolly GP , Zgonis T & Blume P: Soft tissue reconstruction of the diabetic foot. Clin Podiatr Med Surg 20: 757, 2003.
-
19.
Prompers L , Huijberts M & Apelqvist J et al.: High prevalence of ischaemia, infection and serious comorbidity in patients with diabetic foot disease in Europe: baseline results from the Eurodiale study. Diabetologia 50: 18, 2007.
-
20.
Van Battum P , Schaper N & Prompers L et al.: Differences in minor amputation rate in diabetic foot disease throughout Europe are in part explained by differences in disease severity at presentation. Diabet Med 28: 199, 2011.
-
21.
Hobizal KB & Wukich DK: Diabetic foot infections: current concept review. Diabet Foot Ankle 3: 18409, 2012.
-
22.
Snyder RJ , Kirsner RS & Warriner RA III et al.: Consensus recommendations on advancing the standard of care for treating neuropathic foot ulcers in patients with diabetes. Ostomy Wound Manage 56 (suppl): S1, 2010.
-
23.
McKinnon PS , Paladino JA & Grayson ML et al.: Cost-effectiveness of ampicillin/sulbactam versus imipenem/cilastatin in the treatment of limb-threatening foot infections in diabetic patients. Clin Infect Dis 24: 57, 1997.
-
24.
Diamantopoulos EJ , Haritos D & Yfandi G et al.: Management and outcome of severe diabetic foot infections. Exp Clin Endocrinol Diabetes 106: 346, 1998.
-
25.
Calhoun JH , Overgaard KA & Stevens CM et al.: Diabetic foot ulcers and infections: current concepts. Adv Skin Wound Care 15: 31, 2002.
-
26.
Tan JS , Friedman NM & Hazelton-Miller C et al.: Can aggressive treatment of diabetic foot infections reduce the need for above-ankle amputation? Clin Infect Dis 23: 286, 1996.
-
27.
Dinh T , Tecilazich F & Kafanas A et al.: Mechanisms involved in the development and healing of diabetic foot ulceration. Diabetes 61: 2937, 2012.
-
28.
Hemmingsen B , Lund SS & Gluud C et al.: Targeting intensive glycaemic control versus targeting conventional glycaemic control for type 2 diabetes mellitus. Cochrane Database Syst Rev 11: CD008143, 2013.
-
29.
Hasan R , Firwana B & Elraiyah T et al.: A systematic review and meta-analysis of glycemic control for the prevention of diabetic foot syndrome. J Vasc Surg 63 (suppl): 22S, 2016.
-
30.
Markuson M , Hanson D & Anderson J et al.: The relationship between hemoglobin A(1c) values and healing time for lower extremity ulcers in individuals with diabetes. Adv Skin Wound Care 22: 365, 2009.
-
31.
Chamberlain JJ , Doyle-Delgado K & Peterson L et al.: Diabetes technology: review of the 2019 American Diabetes Association Standards of Medical Care in Diabetes. Ann Intern Med 171: 415, 2019.
-
32.
Söylemez MS , Özkan K & Kılıç B et al.: Intermittent negative pressure wound therapy with instillation for the treatment of persistent periprosthetic hip infections: a report of two cases. Ther Clin Risk Manag 12: 161, 2016.
-
33.
Suh HS & Hong JP: Diabetic foot ulcer. J Korean Med Assoc 58: 795, 2015.
-
34.
Armstrong DG & Lavery LA; Diabetic Foot Study Consortium: Negative pressure wound therapy after partial diabetic foot amputation: a multicentre, randomised controlled trial. Lancet 366: 1704, 2005.
-
35.
Sepúlveda G , Espíndola M & Maureira M et al.: Negative-pressure wound therapy versus standard wound dressing in the treatment of diabetic foot amputation: a randomised controlled trial [in Spanish]. Cir Esp 86: 171, 2009.
-
36.
Birke-Sorensen H & Malmsjö Rome P et al.: Evidence-based recommendations for negative pressure wound therapy: treatment variables (pressure levels, wound filler and contact layer)—steps towards an international consensus. J Plast Reconstr Aesthet Surg 64 (suppl): S1, 2011.
-
37.
Borgquist O , Ingemansson R & Malmsjö M: Wound edge microvascular blood flow during negative-pressure wound therapy: examining the effects of pressures from −10 to −175 mmHg. Plast Reconstr Surg 125: 502, 2010.
-
38.
Apelqvist J , Willy C & Fagerdahl AM et al.: Negative pressure wound therapy: overview, challenges and perspectives. J Wound Care 26 (suppl 3): S1, 2017.
-
39.
Tamer S: “Split-Thickness Skin Grafts,” in Skin Grafts: Indications, Applications and Current Research, edited by Spear, M p 3, IntechOpen, London, 2011.
-
40.
Stal S , Spira M & Hamilton S: Skin morphology and function. Clin Plast Surg 14: 201, 1987.
-
41.
Smuđ-Orehovec S , Mance M & Halužan D et al.: Defect reconstruction of an infected diabetic foot using split- and full-thickness skin grafts with adjuvant negative pressure wound therapy: a case report and review of the literature. Wounds 30: 108, 2018.
-
42.
Stein MD , Salkin LM & Freedman AL et al.: Collagen sponge as a topical hemostatic agent in mucogingival surgery. J Periodontol 56: 35, 1985.
-
43.
Baumeister S , Dragu A & Jester A et al.: The role of plastic and reconstructive surgery within an interdisciplinary treatment concept for diabetic ulcers of the foot [in German]. Dtsch Med Wochensch 129: 676, 2004.
-
44.
Anderson JJ , Wallin KJ & Spencer L: Split thickness skin grafts for the treatment of non-healing foot and leg ulcers in patients with diabetes: a retrospective review. Diabet Foot Ankle 3: 10204, 2012.
-
45.
Rosenberg CS: Wound healing in the patient with diabetes mellitus. Nurs Clin North Am 25: 247, 1990.
-
46.
Krishnan ST , Quattrini C & Jeziorska M et al.: Neurovascular factors in wound healing in the foot skin of type 2 diabetic subjects. Diabetes Care 30: 3058, 2007.
-
47.
Ramanujam CL , Han D & Fowler S et al.: Impact of diabetes and comorbidities on split-thickness skin grafts for foot wounds. JAPMA 103: 223, 2013.
-
48.
Donegan RJ , Schmidt BM & Blume PA: An overview of factors maximizing successful split-thickness skin grafting in diabetic wounds. Diabet Foot Ankle 5: 24769, 2014.
-
49.
Ramanujam CL , Stapleton JJ & Kilpadi KL et al.: Split-thickness skin grafts for closure of diabetic foot and ankle wounds: a retrospective review of 83 patients. Foot Ankle Spec 3: 231, 2010.
-
50.
Baker N & Osman IS: The principles and practicalities of offloading diabetic foot ulcers. Diabet Foot J 19: 172, 2016.
-
51.
Shaw JE , van Schie CHM & Carrington AL et al.: An analysis of dynamic forces transmitted through the foot in diabetic neuropathy. Diabetes Care 21: 1955, 1998.
-
52.
de Oliveria AL & Moore AL: Treatment of the diabetic foot by offloading: a systematic review. J Wound Care 24: 562, 2015.
-
53.
Bus SA: The role of pressure offloading on diabetic foot ulcer healing and prevention of recurrence. Plast Reconstr Surg 138 (suppl): 179S, 2016.
-
54.
Health Quality Ontario: Fibreglass total contact casting, removable cast walkers, and irremovable cast walkers to treat diabetic neuropathic foot ulcers: a health technology assessment. Ont Health Technol Assess Ser 17: 1, 2017.
-
55.
Hissink RJ , Manning HA & van Baal JG: The MABAL shoe, an alternative method in contact casting for the treatment of neuropathic diabetic foot ulcers. Foot Ankle Int 21: 320, 2000.
-
56.
Bonanno DR & Gillies EJ: Flexor tenotomy improves healing and prevention of diabetes-related toe ulcers: a systematic review. J Foot Ankle Surg 56: 600, 2017.
-
57.
Ö, Tan , Atik B & Ergen D et al.: Compare of dry open and wet closed dressing technique in split thickness skin grafts. Van Med J 14: 1, 2007.
-
58.
Bilgiç Mİ , Akan M & Çalıkapan GT et al.: Effectiveness of EMLA in split thickness skin graft donor site pain management. Turk Plast Surg 15: 150, 2008.
-
59.
Delice EY & Ulus B: The donor site pain assessment of the patients who were reconstructed split-thickness graft [in Turkish]. Agri 27: 205, 2015.
-
60.
Guo S & Dipietro LA: Factors affecting wound healing. J Dent Res 89: 219, 2010.
-
61.
Thourani VH , Ingram WL & Feliciano DV: Factors affecting success of split-thickness skin grafts in the modern burn unit. J Trauma 54: 562, 2003.
-
62.
Mahmoud SM , Mohamed AA & Mahdi SE et al.: Split-skin graft in the management of diabetic foot ulcers. J Wound Care 17: 303, 2008.
Can Intralesional Epidermal Growth Factor Reduce Skin Graft Applications in Patients with Diabetic Foot Ulcer?
Search for other papers by Bayram Colak in
Current site
Google Scholar
PubMed
Search for other papers by Serdar Yormaz in
Current site
Google Scholar
PubMed
Search for other papers by Ilhan Ece in
Current site
Google Scholar
PubMed
Search for other papers by Mustafa Sahin in
Current site
Google Scholar
PubMed
Background
Diabetic foot ulcer (DFU) is a serious health problem. Major amputation increases the risk of mortality in patients with DFU; therefore, treatment methods other than major amputation come to the fore for these patients. Graft applications create an appropriate environment for the reproduction of epithelial cells. Similarly, epidermal growth factor (EGF) also stimulates epithelization and increases epidermis formation. In this study, we aimed to compare patients with DFU treated with EGF and those treated with a split-thickness skin graft.
Methods
Patients who were treated for DFU in the general surgery clinic were included in the study. The patients were evaluated retrospectively according to their demographic characteristics, wound characteristics, duration of treatment, and treatment modalities.
Results
There were 26 patients in the EGF group and 21 patients in the graft group. The mean duration of treatment was 7 weeks (4-8 weeks) in the EGF group and 5.3 weeks (4-8 weeks) in the graft group (P < .05). In the EGF group, wound healing could not be achieved in one patient during the study period. In the graft group, no recovery was achieved in three patients (14.2%) in the donor site. Graft loss was detected in four patients (19%), and partial graft loss was observed in three patients (14.2%). The DFU of these patients were on the soles (85.7%). These patients have multiple comorbidities.
Conclusions
EGF application may be preferred to avoid graft complications in the graft area and the donor site, especially in elderly patients with multiple comorbidities and wounds on the soles.
Department of General Surgery, Faculty of Medicine, Selcuk University, Konya, Turkey.
Conflict of Interest: None reported.
advertising
